Background: The use of aprotinin during cardiopulmonary bypass may be associated with renal dysfunction due to renal excretion of excess drug. We hypothesized that the difference between standard celite activated clotting time (ACT), which is prolonged by aprotinin, and kaolin ACT could provide an estimate of aprotinin blood level. Methods: Fresh porcine blood was collected from six donor pigs and heparinized. Blood was stored at 4°C, rewarmed and aprotinin was added: 0, 100, 200, and 400 kallikrein inhibitor units/ml. Specimens were incubated at 37°C. Two pairs of ACT tubes (one celite and one kaolin) were measured at 37°C and 20°C using two Hemochron 401 machines. A generalized estimating equation (GEE) statistical approach was used to estimate actual aprotinin from differences in celite and kaolin ACT. Result: There was a significant relationship of the form y = exp (a+bx) between aprotinin concentration and the difference between celite and kaolin ACT at both 37°C (R 2 = 0.858) and 20°C (R 2 = 0.743). Conclusion: The time difference between celite and kaolin ACT may be a simple and inexpensive method for measuring the blood level of aprotinin during cardiopulmonary bypass. This technique may improve patient-specific dosing of aprotinin and reduce the risk of postoperative renal complications.
Introduction
The use of aprotinin remains controversial. In 2006, Mangano et al. reported that aprotinin increases the risk of renal dysfunction after coronary artery surgery. 1 Although some investigators have suggested that using aprotinin in cardiac surgery is safe and that it may even improve kidney function and decrease tubular cell apoptosis after renal ischemia, 2,3 many believe that aprotinin can induce renal dysfunction in a dose-dependent manner by overloading the tubular re-absorption mechanisms. 4 This situation might arise from the administration of aprotinin according to the standard "full-dose Hammersmith" regimen in adults, which is not adjusted according to body surface area or pre-existing renal impairment. 5 Although investigators have tried to find the optimal dose of aprotinin for preventing overdosing, they have been hampered by the lack of a simple method for measuring aprotinin concentration in the blood intraoperatively. 6 We hypothesized that intraoperative aprotinin concentration could be estimated by the difference between standard celite activated clotting time (ACT), which is prolonged in the presence of aprotinin, and kaolin ACT which is not affected by aprotinin. The purpose of the current study was to investigate whether the difference between celite ACT and kaolin ACT would allow accurate estimation of aprotinin concentration in blood.
Methods
Fresh porcine blood was collected into four 50 ml tubes from six donor pigs and heparinized (3 IU/ml, porcine Heparin, Baxter, Deerfield, IL). Blood was stored at 4°C until measurement, rewarmed to 37°C and aprotinin added: 0, 100, 200, and 400 KIU/ml. Specimens were incubated for 30 minutes. Two pairs of ACT tubes (one celite, one kaolin) were measured at 37°C using two alternating Hemochron 401 machines (ACT ranges 0-1500 sec.). The Hemochron 401 has a heater to maintain temperature at 37°C. Usually, celite ACT is longer than kaolin ACT. This difference results mostly from the presence of aprotinin. Specimens were then cooled to 20°C for 15 minutes and ACTs were measured in the same fashion. Generalized estimating equations (GEE) were used to estimate the aprotinin concentration, based on the difference between celite and kaolin ACTs, taking multiple measurements into account and the Wald test to assess significance. 7 We compared linear and non-linear models using R-squared and lowest value of the Schwarz Bayesian information criterion to indicate the preferred model. SPSS version 15.0 was used for statistical analysis (SPSS Inc., Chicago, IL).
Results
Kaolin ACT was not significantly affected by aprotinin concentration while celite ACT was prolonged in a dosedependent manner (Figure 1a , b). Aprotinin concentration at 37°C was estimated by a non-linear model containing kaolin ACT (P = .008) and the difference between celite and kaolin ACT (P < .001), where y = exp (4.364 -0.004 kaolin + 0.013 (celite-kaolin)) . The kaolin ACT is the standard for the level of heparinization while the difference between celite ACT and kaolin ACT results from the aprotinin effect. Similarly, aprotinin at 20°C was estimated by kaolin ACT (P = .002) and the difference between celite and kaolin ACT (P < .001), where y = exp (4.918 -0.003 kaolin + 0.007 (celite-kaolin)) . These equations had good fit to the data (37°C, R 2 = 0.858 and 20°C, R 2 = 0.743) and were used to estimate intraoperative aprotinin concentration at each temperature (Table 1) . Comparisons between the actual aprotinin concentrations versus the estimated values based on kaolin ACT and celite -kaolin ACTs for each donor pig at both 37°C and 20°C are shown in Figure 2 .
Discussion
It has been documented that plasmin is inhibited at a plasma aprotinin concentration of 125 KIU/ml and kallikrein inhibition at a higher level (200-250 KIU/ml). 8 Thus, a concentration of 200-250 KIU/ml was targeted in developing the full-dose Hammersmith regimen. 5 Thus, we did not plan to study blood levels greater than 250 KIU/ml. However, Nuttall and colleagues report that the full dose regimen often results in a level of 300 KIU/ml before cardiopulmonary bypass (CPB) and over 200 KIU/ ml at the end of aprotinin infusion. 6 Aprotinin has a high affinity for renal tissue and is eliminated rapidly from the blood by glomerular filtration. It is stored in the proximal tubular cells and metabolized by renal lysozomes before excretion as active protein. Therefore, aprotinin should be administered as an initial bolus followed by continuous infusion to maintain a targeted blood level. The breakdown of aprotinin can result in kidney dysfunction with albuminuria secondary to overload of the tubular re-absorption mechanisms. 8 We speculate that overdosing with aprotinin results in an excessive blood level of aprotinin, although it is not proven that excessive blood levels or excessive total amount of drug induces renal impairment. Accordingly, avoiding excessive blood levels may be important to avoid renal injury, analogous to the situation with aminoglycoside antibiotics. 4 Traditionally, aprotinin concentration has been measured by enzyme-linked immunosorbent assay (ELISA). 9 O'Connor and colleagues reported a reduction of 0  50  100  150  200  250  300   100  51  100  195  381  744  1454  2841  200  33  65  127  248  484  945  1847  300  22  42  82  161  315  615  1201  400  14  27  54  105  204  400  781  500  9  18  35  68  133  260  507  600  6  12  23  44  86  169  330  700  4  8  15  29  56  110  214  800  3 381  533  745  200  72  101  142  198  277  388  542  300  53  74  103  144  202  282  395  400  38  54  75  105  147  205  287  500  28  39  55  76  107  150  209  600  20  28  40  56  78  109  152  700  15  21  29  40  57  79  111  800  11  15  21  29  41  58 aprotinin clearance and prolongation of aprotinin halflife in patients with renal insufficiency, using the commercially available chromogenic assay kit "Uni-test" (Unicorn Diagnostics Ltd., London UK). 10 However, both ELISA and chromogenic assay methods require 2 or 3 hours to determine aprotinin concentration. It is well known that aprotinin prolongs celite ACT, but not kaolin ACT. Both ACTs are affected by temperature. Dietrich demonstrated that kaolin ACT was not influenced by aprotinin since kaolin bonded nearly completely to aprotinin; however, he recommended using both ACTs for monitoring to ensure safety. 11 We hypothesized that the difference between celite and kaolin ACT could provide an estimate of the aprotinin concentration in blood. This monitoring method estimates aprotinin concentration in blood as demonstrated. It is suggested that this monitoring method will allow the estimation of aprotinin concentration during CPB, even at low temperatures and in patients with low body weight or renal impairment. This method has advantages over other assay techniques with respect to measurement time and cost. Presently, this method does not account for all the effects of CPB and, thus, it is more accurate to estimate aprotinin concentration before or just after starting CPB to avoid overdosing. We also recommend measuring two pairs of ACTs for each patient and averaging to ensure a more reliable estimation. Nevertheless, there is still a possibility of underestimation. We do not recommend increased administration rates of aprotinin when a low level is found, regardless of the dosing schedule, since this technique is designed only to avoid excessive dosing of aprotinin. While further investigations are needed, this method may prove useful in avoiding excessive administrations of aprotinin that may lead to renal injury.
Conclusion
The difference between celite and kaolin ACT may provide a simple and inexpensive method for measuring the blood level of aprotinin during CPB. This technique may improve patient-specific aprotinin dosing and, therefore, reduce the risk of postoperative renal complications.
